Pharmaceutical News

RSS

Mylan releases generic version of Boniva Injection

Mylan Inc. today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva Injection.

5 Sep 2014

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Researchers at the UNC Gillings School of Global Public Health and the UNC School of Medicine have found that a popular class of diabetes medications called DPP-4 inhibitors does not increase the short-term risk of pancreatic cancer, as was previously reported by other researchers.

5 Sep 2014

Keytruda drug gets FDA approval for treatment of advanced melanoma

The U.S. Food and Drug Administration today approved a new immunotherapy drug to treat advanced melanoma, signaling a paradigm shift in the way the deadly skin cancer is treated.

5 Sep 2014

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Debiopharm Group™(Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, today announced that the US Food and Drug Administration (FDA) has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

4 Sep 2014

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Nosopharm, a specialist in the research and development of new anti-infective drugs, announces today its in vitro and in vivo findings for a novel antibacterial class, Odilorhabdins, which has the potential to combat antibiotic resistance.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

E-cigarettes may function as "gateway drug" to marijuana and cocaine

Like conventional cigarettes, electronic cigarettes (or e-cigarettes) may function as a "gateway drug"—a drug that lowers the threshold for addiction to other substances, such as marijuana and cocaine—according to the 120th Shattuck lecture, presented to the Massachusetts Medical Society by Columbia researchers Denise and Eric Kandel and published today in the online edition of the New England Journal of Medicine.

4 Sep 2014

Researcher discovers that aspirin prevents first attack

The first researcher in the world to discover that aspirin prevents a first attack, Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a comprehensive review in the current issue of the journal Trends in Cardiovascular Medicine.

3 Sep 2014

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Infinity Pharmaceuticals, Inc. and AbbVie Inc. today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.

3 Sep 2014

Teens and young adults face high risk from opioid-involved overdose

The prevalence of opioid-involved overdoses has become an increasing concern to health officials both in NYC and nationally.

3 Sep 2014

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder.

3 Sep 2014

Novel polypill increases patient adherence to treatment following heart attack

New research shows a novel polypill increases patient adherence to treatment following a myocardial infarction (MI) or heart attack, according to new study results reported at the European Society of Cardiology's ESC Congress 2014 in Barcelona, Spain.

3 Sep 2014

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

CleveXel Pharma today announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products.

3 Sep 2014

Researchers create new drug to reduce inflammation of donor organ after transplantation

To reduce the number of discards and thus make more kidneys available, researchers and medical scientists from the European consortium MABSOT have created a new drug called OPN-305 to reduce inflammation of the donor organ after transplantation.

3 Sep 2014

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic.

2 Sep 2014

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.

2 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI) is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 today.

2 Sep 2014

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.

2 Sep 2014

Pharmaceutical News

Mylan releases generic version of Boniva Injection

Short-term use of DPP-4 inhibitors does not increase risk for pancreatic cancer

Keytruda drug gets FDA approval for treatment of advanced melanoma

FDA provides QIDP designation to Debiopharm’s Debio 1450 for treatment of ABSSSI

Nosopharm reports findings on Odilorhabdins that has potential to combat antibiotic resistance

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

E-cigarettes may function as "gateway drug" to marijuana and cocaine

Researcher discovers that aspirin prevents first attack

Infinity and AbbVie enter into global collaboration to develop and commercialize duvelisib

Teens and young adults face high risk from opioid-involved overdose

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Novel polypill increases patient adherence to treatment following heart attack

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Researchers create new drug to reduce inflammation of donor organ after transplantation

Amgen seeks EMA approval for marketing talimogene laherparepvec

VentiRx's motolimod receives FDA Fast Track designation for ovarian cancer treatment

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Ambulance administration of antiplatelet medication may help heart attack patients

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News